抗生素抗藥性市場,按疾病類型、病原體類型、藥物類別、最終用戶、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1358223

抗生素抗藥性市場,按疾病類型、病原體類型、藥物類別、最終用戶、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Antibiotic Resistance Market, By Disease Type, By Pathogen Type, By Drug Class, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年抗生素抗藥性市場規模為 80.057 億美元,2023 年至 2030 年複合年成長率為 6.1%。

抗生素抗藥性市場 - 市場動態:

  • 增加細菌感染的流行以促進市場成長
  • 對傳統抗生素產生抗藥性的細菌性疾病的日益流行可能會增加對新療法的需求,從而推動市場成長。隨著抗生素抗藥性的蔓延,對新抗生素的需求變得更加緊迫。這可能會導致製藥公司增加研發投資。對細菌感染負擔的全球綜合估計已經發布。 2019年,全球有770萬人死亡與細菌感染有關。這相當於全球死亡人數的八分之一。人工智慧和機器學習在藥物研究中的整合為加速新型抗生素的創造提供了成長機會。然而,抗生素抗藥性並未得到一般大眾甚至醫療保健提供者的廣泛認可。這可能導致不正確的處方和濫用。

抗生素抗藥性市場 - 主要見解:

  • 根據我們的研究分析師分享的分析,預計全球抗生素抗藥性市場在預測期內(2023-2030 年)每年將以 6.1% 左右的複合年成長率成長
  • 根據疾病類型細分,預計泌尿道感染將在 2022 年顯示最大的市場佔有率
  • 根據病原體類型細分,鮑曼不動桿菌是 2022 年的主導類型
  • 根據藥物類別細分,噁唑烷酮類藥物是 2022 年的主導類型
  • 根據最終用戶細分,醫院是 2022 年的主導類型
  • 按地區分類,北美是 2022 年的主要收入來源

抗生素抗藥性市場-細分分析:

  • 全球抗生素抗藥性市場根據疾病類型、病原體類型、藥物類別、最終用戶和地區進行細分。
  • 依疾病類型,市場分為四類:泌尿道感染、腹腔內感染、血流感染、艱難梭菌感染等。尿路感染主導市場成長。泌尿道感染是影響人類,尤其是女性最常見的細菌性疾病之一。尿路感染通常用抗生素治療。然而,隨著抗生素抗藥性的日益普遍,管理和治療泌尿道感染變得更加困難。
  • 依病原體類型,市場分為四大類:鮑曼不動桿菌、綠膿桿菌、金黃色葡萄球菌、肺炎鏈球菌等。鮑曼不動桿菌主導市場成長。鮑曼不動桿菌具有快速獲得抗藥性機制的固有傾向,使其成為醫院環境中最麻煩的感染之一,特別是在重症監護病房 (ICU) 中。
  • 根據藥物類別,市場分為三類:噁唑烷酮類、脂糖肽類、四環素類和其他。噁唑烷酮類產業在市場中佔據主導地位,並可能在預測期內保持其主導地位。噁唑烷酮是用於治療細菌感染的抗生素,特別是革蘭氏陽性病原體引起的感染。利奈唑胺是最知名的噁唑烷酮。它們尤其重要,因為它們已被證明可有效對抗多重抗藥性病原體,包括抗甲氧西林金黃色葡萄球菌(MRSA)和耐萬古黴素腸球菌(VRE)。
  • 根據最終用戶,市場分為三類:醫院、家庭護理、專科診所和其他。醫院產業在市場上佔據主導地位。醫院對於抗生素抗藥性的發展至關重要。它們既是抗藥性細菌的滋生地,也是治療超級細菌患者的主戰場。面對抗生素抗藥性的發展,醫院的影響是複雜的,對醫療保健市場也產生了相當大的影響。

抗生素抗藥性市場 - 地理洞察:

從地理來看,該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。由於傳染病的流行和醫療保健支出的增加,預計北美將主導市場的成長。北美,特別是美國,爆發了多種傳染病,其中一些具有抗生素抗藥性。例如,MRSA(耐甲氧西林金黃色葡萄球菌)已成為美國許多醫院和醫療機構的主要關注點。美國在人均醫療保健上的支出比世界上任何其他國家都多。據美國醫學協會稱,很大一部分收入用於研究、藥物開發和診斷。 2021 年,美國醫療保健支出成長 2.7%,達到 4.3 兆美元,即人均 12,914 美元。這一成長率大幅低於 2020 年(10.3%)。由於對有效抗生素療法的需求不斷成長,預計歐洲和亞太地區對雙特異性抗藥性市場的需求將會增加。

抗生素抗藥性市場-競爭格局:

抗生素抗藥性已成為全球關注的主要議題。隨著細菌進化並對現有藥物產生抗藥性,感染的治療變得更加困難,導致病程更長、住院次數增加以及死亡率上升。生產商一直積極進行抗生素研究,但迫於經濟壓力,一些大型製藥公司減少或停止了抗生素研究計畫。輝瑞、默克、葛蘭素史克和羅氏代表了一些涉足製藥業的公司。全面的競爭性研究必須考慮製藥公司、診斷公司、研究機構和替代治療方式。例如,2021 年5 月,巴塞利亞製藥有限公司(Basilea Pharmaceutical Ltd.,股票代碼:BSLN)今天宣布,它已獲得CARB-X(抗擊抗生素抗藥性細菌生物製藥加速器)高達270 萬美元的資助, CARB-X 是一家全球合作夥伴,致力於支持抗菌產品的早期開發,以診斷、預防和治療抗藥性感染。

最近的發展:

2020 年 11 月 18 日,默克(在美國和加拿大以外地區稱為 MSD)最近宣布推出全球抗菌素抗藥性趨勢監測研究 (SMART) 新網站。 SMART 於 2002 年啟動,是世界上規模最大、運行時間最長的抗菌素抗藥性 (AMR) 監測研究之一,涵蓋 60 多個國家的 200 多個地點。

目錄

第一章:抗生素抗藥性市場概述

  • 研究範圍
  • 市場預估年份

第 2 章:執行摘要

  • 市場片段
    • 按疾病類型分類的抗生素抗藥性市場片段
    • 按病原體類型分類的抗生素抗藥性市場片段
    • 按藥物類別分類的抗生素抗藥性市場片段
    • 最終用戶的抗生素抗藥性市場片段
    • 按國家/地區分類的抗生素抗藥性市場片段
    • 按地區分類的抗生素抗藥性市場片段
  • 競爭洞察

第 3 章:抗生素抗藥性主要市場趨勢

  • 抗生素抗藥性市場促進因素
    • 市場促進因素的影響分析
  • 抗生素抗藥性市場限制
    • 市場限制影響分析
  • 抗生素抗藥性市場機會
  • 抗生素抗藥性市場未來趨勢

第 4 章:抗生素抗藥性產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章:抗生素抗藥性市場:COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章:抗生素抗藥性市場格局

  • 2022 年抗生素抗藥性市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章:抗生素抗藥性市場 - 依疾病類型

  • 概述
    • 按疾病類型分類的細分市場佔有率分析
    • 泌尿道感染
    • 腹腔內感染
    • 血流感染
    • 艱難梭菌感染
    • 其他

第 8 章:抗生素抗藥性市場 - 依病原體類型

  • 概述
    • 按病原體類型分類的細分市場佔有率分析
    • 鮑曼不動桿菌
    • 銅綠假單胞菌
    • 金黃色葡萄球菌
    • 肺炎鏈球菌
    • 其他

第 9 章:抗生素抗藥性市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 噁唑烷酮類
    • 脂糖肽
    • 四環素類
    • 其他

第 10 章:抗生素抗藥性市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 居家護理
    • 專科診所
    • 其他

第 11 章:抗生素抗藥性市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗生素抗藥性主要製造商
    • 北美市場規模和預測(按國家)
    • 北美市場規模和預測(按疾病類型)
    • 北美市場規模和預測(按病原體類型)
    • 北美市場規模和預測(按藥物類別)
    • 北美市場規模和預測(按最終用戶)
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗生素抗藥性主要製造商
    • 歐洲市場規模和預測(按國家)
    • 歐洲市場規模與預測(按疾病類型)
    • 歐洲市場規模和預測(按病原體類型)
    • 歐洲市場規模和預測(按藥物類別)
    • 歐洲市場規模和預測(按最終用戶)
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區抗生素抗藥性主要製造商
    • 亞太地區市場規模與預測(按國家)
    • 亞太地區市場規模與預測(按疾病類型)
    • 亞太地區市場規模和預測(按病原體類型)
    • 亞太地區市場規模和預測(按藥物類別)
    • 亞太地區市場規模和預測(按最終用戶)
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗生素抗藥性主要製造商
    • 拉丁美洲市場規模與預測(按國家)
    • 拉丁美洲市場規模與預測(按疾病類型)
    • 拉丁美洲市場規模和預測(按病原體類型)
    • 拉丁美洲市場規模與預測(按藥物類別)
    • 拉丁美洲市場規模和預測(按最終用戶)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲抗生素抗藥性主要製造商
    • 中東和非洲市場規模及預測(按國家)
    • 中東和非洲市場規模及預測(按疾病類型)
    • 中東和非洲市場規模及預測(按病原體類型)
    • 中東和非洲市場規模及預測(按藥物類別)
    • 中東和非洲市場規模和預測(按最終用戶)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章:主要供應商分析 - 抗生素抗藥性產業

  • 競爭儀表板
  • 公司簡介
    • Achaogen Inc
    • Nabriva Therapeutics plc
    • BioVersys AG
    • Johnson & Johnson Services, Inc.
    • Destiny Pharma plc
    • Armata Pharmaceuticals, Inc.
    • West Way Health
    • The Medicines Company
    • Merck & Co., Inc.
    • Pfizer Inc.
    • CARB-X
    • Melinta Therapeutics LLC
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • GSK plc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd

第 13 章:360 度分析師視角

第 14 章:附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1722

REPORT HIGHLIGHT

Antibiotic Resistance Market size was valued at USD 8,005.7 million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.

Antibiotic resistance emerges when bacteria adapt to the usage of these medications. It develops in bacteria instead of people or animals. These bacteria can infect humans and animals, and their infections are more difficult to treat than infections caused by non-resistant bacteria. Antibiotic resistance is accelerated by antibiotic abuse and overuse, as well as inadequate infection prevention and control. At all levels of society, steps can be made to decrease the impact and spread of resistance. Antibiotic resistance is a global issue and requires cooperation between nations, industries, and organizations. Investing in the development of new antibiotics, as well as alternative therapies like bacteriophages and antimicrobial peptides. For example, Methicillin-Resistant Staphylococcus Aureus (MRSA's) emergence and spread show the quick rate at which germs can adapt to drugs, as well as the continual problem that healthcare personnel face in treating bacterial illnesses. It emphasizes the critical need for effective antibiotic usage, improved infection control procedures, and the discovery of novel antibiotics.

Antibiotic Resistance Market - Market Dynamics:

  • Increasing the prevalence of bacterial infection to increase market growth
  • The increasing prevalence of bacterial illnesses resistant to conventional antibiotics may increase demand for novel remedies, driving market growth. As antibiotic resistance spreads, the need for new antibiotics becomes more pressing. This could lead to increased investment in R&D by pharmaceutical corporations. Global comprehensive estimates of the burden of bacterial infections have been published. In 2019, 7.7 million deaths around the world were found to be linked to bacterial infections. That equals 1 in 8 of all global deaths. The integration of AI and machine learning in drug research provides a growth opportunity to accelerate the creation of novel antibiotics. However, Antibiotic resistance is not widely recognized by the general population and even by healthcare providers. This can lead to incorrect prescribing and abuse.

Antibiotic Resistance Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Antibiotic Resistance market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)
  • Based on Disease type segmentation, Urinary Tract Infections was predicted to show maximum market share in the year 2022
  • Based on Pathogen Type segmentation, Acinetobacter Baumannii was the leading type in 2022
  • Based on Drug class segmentation, Oxazolidinones were the leading type in 2022
  • Based on End-User segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Antibiotic Resistance Market- Segmentation Analysis:

  • The Global Antibiotic Resistance Market is segmented on the basis of Disease type, Pathogen Type, Drug class, End-User, and Region.
  • The market is divided into four categories based on Disease type: Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, and Others. Urinary Tract Infections dominate the market growth. UTIs are one of the most common bacterial diseases that affect humans, particularly women. UTIs are often treated with antibiotics. However, with the increasing prevalence of antibiotic resistance, managing and treating UTIs is becoming more difficult.
  • The market is divided into four categories based on Pathogen Type: Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus pneumonia, and Others. Acinetobacter Baumannii dominates the market growth. A. baumannii has an inherent propensity to rapidly acquire resistance mechanisms, making it one of the most troublesome infections in hospital settings, particularly in intensive care units (ICUs).
  • The market is divided into three categories based on Drug class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others. The Oxazolidinones sector dominates the market and is likely to maintain its dominance during the forecast period. Oxazolidinones are antibiotics that are used to treat bacterial infections, particularly those caused by Gram-positive pathogens. Linezolid is the most well-known oxazolidinone. They are especially significant since they have been shown to be effective against multi-drug resistance pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
  • The market is divided into three categories based on End-User: Hospitals, Homecare, Specialty Clinics, and Others. The hospital sector dominates the market. Hospitals are essential to the development of antibiotic resistance. They are both a breeding ground for resistant bacteria and a main battleground for treating people sick with these superbugs. The implications for hospitals in the face of developing antibiotic resistance are complex, with considerable ramifications for the healthcare market.

Antibiotic Resistance Market - Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market, due to the increasing prevalence of infectious diseases and rising healthcare expenditure. North America, especially the United States, has had outbreaks of many infectious diseases, some of which are antibiotic-resistant. MRSA (Methicillin-resistant Staphylococcus aureus), for example, has become a major concern in many U.S. hospitals and healthcare settings. The United States spends more on healthcare per capita than any other country in the world. According to the American Medical Association, a significant amount of the revenue is spent on research, drug development, and diagnostics. Health spending in the U.S. increased by 2.7% in 2021 to USD 4.3 trillion or USD 12,914 per capita. This growth rate is substantially lower than in 2020 (10.3% percent). Europe and Asia Pacific are projected to demand for Bispecific Resistance Market, due to the growing demand for effective antibiotic therapies.

Antibiotic Resistance Market- Competitive Landscape:

Antibiotic resistance has emerged as a major global concern. As bacteria evolve and become resistant to existing medicines, infections become more challenging to treat, leading to longer illnesses, more hospitalizations, and a rise in mortality. The manufacturers have been active in antibiotic research, however owing to economic pressures, some large pharmaceutical corporations have reduced or discontinued their antibiotic research projects. Pfizer, Merck, GlaxoSmithKline, and Roche represent some of the companies involved in the pharmaceutical industry. A comprehensive competitive study must consider pharmaceutical businesses, diagnostic companies, research institutes, and alternative treatment modalities. For instance, On May 2021, Basilea Pharmaceutical Ltd. (SIX: BSLN) announced today that it has been awarded a grant of up to USD 2.7 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership dedicated to supporting the early development of antibacterial products to diagnose, prevent and treat drug-resistant infections.

Recent Developments:

November 18, 2020, Merck, known as MSD outside the United States and Canada, recently, announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world's largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIBIOTIC RESISTANCE MARKET KEY PLAYERS

  • Achaogen Inc
  • Nabriva Therapeutics plc
  • BioVersys AG
  • Johnson & Johnson Services, Inc.
  • Destiny Pharma plc
  • Armata Pharmaceuticals, Inc.
  • West Way Health
  • The Medicines Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • CARB-X
  • Melinta Therapeutics LLC
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • GSK plc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE TYPE

  • Urinary Tract Infection
  • Intra-Abdominal Infections
  • Blood Stream Infections
  • Clostridium Difficile Infections
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN TYPE

  • Acinetobacter Baumannii
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Streptococcus pneumoniae
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS

  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END-USER

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antibiotic Resistance Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antibiotic Resistance Market Snippet by Disease Type
    • 2.1.2. Antibiotic Resistance Market Snippet by Pathogen Type
    • 2.1.3. Antibiotic Resistance Market Snippet by Drug Class
    • 2.1.4. Antibiotic Resistance Market Snippet by End-User
    • 2.1.5. Antibiotic Resistance Market Snippet by Country
    • 2.1.6. Antibiotic Resistance Market Snippet by Region
  • 2.2. Competitive Insights

3. Antibiotic Resistance Key Market Trends

  • 3.1. Antibiotic Resistance Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antibiotic Resistance Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antibiotic Resistance Market Opportunities
  • 3.4. Antibiotic Resistance Market Future Trends

4. Antibiotic Resistance Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antibiotic Resistance Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antibiotic Resistance Market Landscape

  • 6.1. Antibiotic Resistance Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antibiotic Resistance Market - By Disease Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2022 & 2030 (%)
    • 7.1.2. Urinary Tract Infection
    • 7.1.3. Intra-Abdominal Infections
    • 7.1.4. Blood Stream Infections
    • 7.1.5. Clostridium Difficile Infections
    • 7.1.6. Others

8. Antibiotic Resistance Market - By Pathogen Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Pathogen Type, 2022 & 2030 (%)
    • 8.1.2. Acinetobacter Baumannii
    • 8.1.3. Pseudomonas Aeruginosa
    • 8.1.4. Staphylococcus Aureus
    • 8.1.5. Streptococcus pneumoniae
    • 8.1.6. Others

9. Antibiotic Resistance Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 9.1.2. Oxazolidinones
    • 9.1.3. Lipoglycopeptides
    • 9.1.4. Tetracyclines
    • 9.1.5. Others

10. Antibiotic Resistance Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2022 & 2030 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Specialty Clinics
    • 10.1.5. Others

11. Antibiotic Resistance Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antibiotic Resistance Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antibiotic Resistance Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antibiotic Resistance Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antibiotic Resistance Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antibiotic Resistance Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Antibiotic Resistance Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Achaogen Inc
    • 12.2.2. Nabriva Therapeutics plc
    • 12.2.3. BioVersys AG
    • 12.2.4. Johnson & Johnson Services, Inc.
    • 12.2.5. Destiny Pharma plc
    • 12.2.6. Armata Pharmaceuticals, Inc.
    • 12.2.7. West Way Health
    • 12.2.8. The Medicines Company
    • 12.2.9. Merck & Co., Inc.
    • 12.2.10. Pfizer Inc.
    • 12.2.11. CARB-X
    • 12.2.12. Melinta Therapeutics LLC
    • 12.2.13. Novartis AG
    • 12.2.14. Vertex Pharmaceuticals Incorporated
    • 12.2.15. GSK plc.
    • 12.2.16. AbbVie Inc.
    • 12.2.17. F. Hoffmann-La Roche Ltd

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antibiotic Resistance Market: Disease Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type
  • TABLE Global Antibiotic Resistance Market, by Disease Type 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Pathogen Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Pathogen Type
  • TABLE Global Antibiotic Resistance Market, by Pathogen Type 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Antibiotic Resistance Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: End-User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Antibiotic Resistance Market, by End-User 2018-2030 (USD Million)
  • TABLE Antibiotic Resistance Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antibiotic Resistance Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Disease Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Pathogen Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antibiotic Resistance Market, by End-User, 2018-2030 (USD Million)